Helix BioPharma Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HBPCF research report →
Price Chart
About the company
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2).
- CEO
- Thomas Mehrling
- IPO
- 2009
- Employees
- 7
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on HBPCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $58.81M
- P/E
- -20.91
- PEG
- -0.08
- P/S
- 0.00
- P/B
- 4.78
- EV/EBITDA
- -21.98
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -21.54%
- ROIC
- -21.65%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-7,217.7+28.8%
- Op Income
- $-5,000,000
- Net Income
- $-5,000,000-53872.4%
- EPS
- $-0.07-67300.0%
- OCF Growth
- +23.4%
- FCF Growth
- +23.6%
- 52W High
- $1.73
- 52W Low
- $0.60
- 50D MA
- $1.54
- 200D MA
- $1.68
- Beta
- -0.35
- RSI (14)
- 0
- Avg Volume
- 3
No earnings-call transcripts are available for HBPCF yet.
- Free Float
- 71.1%
- Shares Outstanding
- 76.38M
- Float Shares
- 54.27M
Our HBPCF coverage
Recent articles, reports, and earnings notes.
No research on HBPCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HBPCF report →Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
thenewswire.com · Aug 17
Helix Biopharma Corp. Announces Board Composition Changes
thenewswire.com · Aug 14
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
thenewswire.com · Jun 30
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
thenewswire.com · Jun 12
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
thenewswire.com · Jun 3
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
thenewswire.com · May 22
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
thenewswire.com · May 13
Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
thenewswire.com · Mar 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.